

Amendments to the Claims:

1. (Withdrawn) An experimental animal having implanted therein an animal cell to which the gene encoding human tissue factor (TF) or part thereof has been inserted and which is capable of expressing said gene, said animal being a non-human animal in which a hypercoagulable state persists for a long period of time.
2. (Withdrawn) The animal according to claim 1 wherein said part of human tissue factor lacks the intracellular region.
3. (Withdrawn) The animal according to claim 1 wherein said animal cell is a mammalian cell.
4. (Withdrawn) The animal according to claim 3 wherein said mammalian cell is a human myeloma cell.
5. (Withdrawn) The animal according to claim 1 wherein said ~~said~~ animal is a mouse.
6. (Withdrawn) The animal according to claim 1 wherein said hypercoagulable state is indicated by at least one of the phenomena comprising an increase in the plasma concentration of human tissue factor, a decrease in platelets, a decrease in fibrinogen, an increase in the concentration of soluble fibrin monomer complex, and an increase in the concentration of thrombin-antithrombin III complex.
7. (Withdrawn) A method of generating the animal according to claim 1, wherein an animal cell to which the gene encoding human tissue factor (TF) or part thereof has been inserted and which is capable of expressing said gene is implanted to non-human animals and then an animal having a persistent hypercoagulable state is selected.
8. (Withdrawn) A method of screening an anti-thrombotic agent which method comprises using the animal according to claim 1.
9. (Previously presented) A method for treating a disease having a persistent hypercoagulable state comprising administering a therapeutically effective amount of an antibody to human tissue factor (human TF) to a patient in need thereof.
10. (Previously presented) The method according to claim 9 wherein said antibody is a polyclonal antibody.

11. (Previously presented) The method according to claim 9 wherein said antibody is a monoclonal antibody.

12. (Previously presented) The method according to claim 9 wherein said antibody is a recombinant antibody.

13. (Previously presented) The method according to claim 9 wherein said antibody is an altered antibody.

14. (Previously presented) The method according to claim 13 wherein said altered antibody is a chimeric antibody or a humanized antibody.

15. (Previously presented) The method according to claim 14 wherein said humanized antibody is a humanized antibody of version b-b, i-b, or i-b2.

16. (Previously presented) The method according to claim 9 wherein said antibody is a modified antibody.

17. (Previously presented) The method according to claim 16 wherein said modified antibody is an antibody fragment Fab, F(ab')₂, or Fv, or a single chain Fv (scFv).

18-26. (Canceled)

27. (Previously presented) A method for treating venous thrombosis comprising administering a therapeutically effective amount of an antibody to human tissue factor (human TF) to a patient in need thereof.

28. (Previously presented) The method according to claim 27 wherein said antibody is a polyclonal antibody.

29. (Previously presented) The method according to claim 27 wherein said antibody is a monoclonal antibody.

30. (Previously presented) The method according to claim 27 wherein said antibody is a recombinant antibody.

31. (Previously presented) The method according to claim 27 wherein said antibody is an altered antibody.

32. (Previously presented) The method according to claim 31 wherein said altered antibody is a chimeric antibody or a humanized antibody.

33. (Previously presented) The method according to claim 32 wherein said humanized antibody is a humanized antibody of version b-b, i-b, or i-b2.

34. (Previously presented) The method according to claim 27 wherein said antibody is a modified antibody.

35. (Previously presented) The method according to claim 34 wherein said modified antibody is an antibody fragment Fab, F(ab')₂, or Fv, or a single chain Fv (scFv).

36. (Previously presented) A method for treating arterial thrombosis administering a therapeutically effective amount of an antibody to human tissue factor (human TF) to a patient in need thereof.

37. (Previously presented) The method according to claim 36 wherein said antibody is a polyclonal antibody.

38. (Previously presented) The method according to claim 36 wherein said antibody is a monoclonal antibody.

39. (Previously presented) The method according to claim 36 wherein said antibody is a recombinant antibody.

40. (Previously presented) The method according to claim 36 wherein said antibody is an altered antibody.

41. (Previously presented) The method according to claim 40 wherein said altered antibody is a chimeric antibody or a humanized antibody.

42. (Previously presented) The method according to claim 41 wherein said humanized antibody is a humanized antibody of version b-b, i-b, or i-b2.

43. (Previously presented) The method according to claim 36 wherein said antibody is a modified antibody.

44. (Previously presented) The method according to claim 43 wherein said modified antibody is an antibody fragment Fab, F(ab')₂, or Fv, or a single chain Fv (scFv).

45. (Previously presented) A method for treating disease resulting from the medial thickening of the vessels comprising administering a therapeutically effective amount of an antibody to human tissue factor (human TF) to a patient in need thereof.

46. (Previously presented) The method according to claim 45 wherein said antibody is a polyclonal antibody.

47. (Previously presented) The method according to claim 45 wherein said antibody is a monoclonal antibody.

48. (Previously presented) The method according to claim 45 wherein said antibody is a recombinant antibody.

49. (Previously presented) The method according to claim 45 wherein said antibody is an altered antibody.

50. (Previously presented) The method according to claim 49 wherein said altered antibody is a chimeric antibody or a humanized antibody.

51. (Previously presented) The method according to claim 50 wherein said humanized antibody is a humanized antibody of version b-b, i-b, or i-b2.

52. (Previously presented) The method according to claim 45 wherein said antibody is a modified antibody.

53. (Previously presented) The method according to claim 52 wherein said modified antibody is an antibody fragment Fab, F(ab')₂, or Fv, or a single chain Fv (scFv).